Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.
Identifieur interne : 000139 ( Main/Exploration ); précédent : 000138; suivant : 000140Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.
Auteurs : Hywel D. Williams [Australie] ; Leigh Ford [Australie] ; Shea Lim [Australie] ; Sifei Han [Australie] ; John Baumann [États-Unis] ; Hannah Sullivan [États-Unis] ; David Vodak [États-Unis] ; Annabel Igonin [France] ; Hassan Benameur [France] ; Colin W. Pouton [Australie] ; Peter J. Scammells [Australie] ; Christopher J H. Porter [Australie]Source :
- Journal of pharmaceutical sciences [ 1520-6017 ] ; 2017.
Abstract
Higher lipid solubility of lipophilic salt forms creates new product development opportunities for high-dose liquid-filled capsules. The purpose of this study is to determine if lipophilic salts of Biopharmaceutical Classification System (BCS) Class I amlodipine and BCS Class III fexofenadine, ranitidine, and metformin were better lipid formulation candidates than existing commercial salts. Lipophilic salts were prepared from lipophilic anions and commercial HCl or besylate salt forms, as verified by (1)H-NMR. Thermal properties were assessed by differential scanning calorimetry and hot-stage microscopy. X-ray diffraction and polarized light microscopy were used to confirm the salt's physical form. All lipophilic salt forms were substantially more lipid-soluble (typically >10-fold) when compared to commercial salts. For example, amlodipine concentrations in lipidic excipients were limited to <5-10 mg/g when using the besylate salt but could be increased to >100 mg/g when using the docusate salt. Higher lipid solubility of the lipophilic salts of each drug translated to higher drug loadings in lipid formulations. In vitro tests showed that lipophilic salts solubilized in a lipid formulation resulted in dispersion behavior that was at least as rapid as the dissolution rates of conventional salts. This study confirmed the applicability of forming lipophilic salts of BCS I and III drugs to promote the utility of lipid-based delivery systems.
DOI: 10.1016/j.xphs.2017.05.019
PubMed: 28549907
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 000B82
- to stream PubMed, to step Curation: 000B79
- to stream PubMed, to step Checkpoint: 000B79
- to stream Ncbi, to step Merge: 004878
- to stream Ncbi, to step Curation: 004878
- to stream Ncbi, to step Checkpoint: 004878
- to stream Main, to step Merge: 000134
- to stream Main, to step Curation: 000139
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.</title><author><name sortKey="Williams, Hywel D" sort="Williams, Hywel D" uniqKey="Williams H" first="Hywel D" last="Williams">Hywel D. Williams</name><affiliation wicri:level="1"><nlm:affiliation>Capsugel Research & Development, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Electronic address: hywel.williams@capsugel.com.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Capsugel Research & Development, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Ford, Leigh" sort="Ford, Leigh" uniqKey="Ford L" first="Leigh" last="Ford">Leigh Ford</name><affiliation wicri:level="1"><nlm:affiliation>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Lim, Shea" sort="Lim, Shea" uniqKey="Lim S" first="Shea" last="Lim">Shea Lim</name><affiliation wicri:level="1"><nlm:affiliation>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Han, Sifei" sort="Han, Sifei" uniqKey="Han S" first="Sifei" last="Han">Sifei Han</name><affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Baumann, John" sort="Baumann, John" uniqKey="Baumann J" first="John" last="Baumann">John Baumann</name><affiliation wicri:level="2"><nlm:affiliation>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend, Oregon 97703.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend</wicri:cityArea></affiliation></author><author><name sortKey="Sullivan, Hannah" sort="Sullivan, Hannah" uniqKey="Sullivan H" first="Hannah" last="Sullivan">Hannah Sullivan</name><affiliation wicri:level="2"><nlm:affiliation>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend, Oregon 97703.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend</wicri:cityArea></affiliation></author><author><name sortKey="Vodak, David" sort="Vodak, David" uniqKey="Vodak D" first="David" last="Vodak">David Vodak</name><affiliation wicri:level="2"><nlm:affiliation>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend, Oregon 97703.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend</wicri:cityArea></affiliation></author><author><name sortKey="Igonin, Annabel" sort="Igonin, Annabel" uniqKey="Igonin A" first="Annabel" last="Igonin">Annabel Igonin</name><affiliation wicri:level="3"><nlm:affiliation>Capsugel Research & Development, Parc d'Innovation, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Capsugel Research & Development, Parc d'Innovation, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Benameur, Hassan" sort="Benameur, Hassan" uniqKey="Benameur H" first="Hassan" last="Benameur">Hassan Benameur</name><affiliation wicri:level="3"><nlm:affiliation>Capsugel Research & Development, Parc d'Innovation, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Capsugel Research & Development, Parc d'Innovation, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Pouton, Colin W" sort="Pouton, Colin W" uniqKey="Pouton C" first="Colin W" last="Pouton">Colin W. Pouton</name><affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Scammells, Peter J" sort="Scammells, Peter J" uniqKey="Scammells P" first="Peter J" last="Scammells">Peter J. Scammells</name><affiliation wicri:level="1"><nlm:affiliation>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Electronic address: peter.scammells@monash.edu.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Porter, Christopher J H" sort="Porter, Christopher J H" uniqKey="Porter C" first="Christopher J H" last="Porter">Christopher J H. Porter</name><affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Electronic address: chris.porter@monash.edu.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28549907</idno><idno type="pmid">28549907</idno><idno type="doi">10.1016/j.xphs.2017.05.019</idno><idno type="wicri:Area/PubMed/Corpus">000B82</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000B82</idno><idno type="wicri:Area/PubMed/Curation">000B79</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000B79</idno><idno type="wicri:Area/PubMed/Checkpoint">000B79</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000B79</idno><idno type="wicri:Area/Ncbi/Merge">004878</idno><idno type="wicri:Area/Ncbi/Curation">004878</idno><idno type="wicri:Area/Ncbi/Checkpoint">004878</idno><idno type="wicri:Area/Main/Merge">000134</idno><idno type="wicri:Area/Main/Curation">000139</idno><idno type="wicri:Area/Main/Exploration">000139</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.</title><author><name sortKey="Williams, Hywel D" sort="Williams, Hywel D" uniqKey="Williams H" first="Hywel D" last="Williams">Hywel D. Williams</name><affiliation wicri:level="1"><nlm:affiliation>Capsugel Research & Development, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Electronic address: hywel.williams@capsugel.com.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Capsugel Research & Development, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Ford, Leigh" sort="Ford, Leigh" uniqKey="Ford L" first="Leigh" last="Ford">Leigh Ford</name><affiliation wicri:level="1"><nlm:affiliation>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Lim, Shea" sort="Lim, Shea" uniqKey="Lim S" first="Shea" last="Lim">Shea Lim</name><affiliation wicri:level="1"><nlm:affiliation>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Han, Sifei" sort="Han, Sifei" uniqKey="Han S" first="Sifei" last="Han">Sifei Han</name><affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Baumann, John" sort="Baumann, John" uniqKey="Baumann J" first="John" last="Baumann">John Baumann</name><affiliation wicri:level="2"><nlm:affiliation>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend, Oregon 97703.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend</wicri:cityArea></affiliation></author><author><name sortKey="Sullivan, Hannah" sort="Sullivan, Hannah" uniqKey="Sullivan H" first="Hannah" last="Sullivan">Hannah Sullivan</name><affiliation wicri:level="2"><nlm:affiliation>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend, Oregon 97703.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend</wicri:cityArea></affiliation></author><author><name sortKey="Vodak, David" sort="Vodak, David" uniqKey="Vodak D" first="David" last="Vodak">David Vodak</name><affiliation wicri:level="2"><nlm:affiliation>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend, Oregon 97703.</nlm:affiliation><country xml:lang="fr">États-Unis</country><placeName><region type="state">Oregon</region></placeName><wicri:cityArea>Capsugel Pharmaceutical Research & Development, 64550 Research Road, Bend</wicri:cityArea></affiliation></author><author><name sortKey="Igonin, Annabel" sort="Igonin, Annabel" uniqKey="Igonin A" first="Annabel" last="Igonin">Annabel Igonin</name><affiliation wicri:level="3"><nlm:affiliation>Capsugel Research & Development, Parc d'Innovation, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Capsugel Research & Development, Parc d'Innovation, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Benameur, Hassan" sort="Benameur, Hassan" uniqKey="Benameur H" first="Hassan" last="Benameur">Hassan Benameur</name><affiliation wicri:level="3"><nlm:affiliation>Capsugel Research & Development, Parc d'Innovation, Strasbourg, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Capsugel Research & Development, Parc d'Innovation, Strasbourg</wicri:regionArea><placeName><region type="region">Grand Est</region><region type="old region">Alsace (région administrative)</region><settlement type="city">Strasbourg</settlement></placeName></affiliation></author><author><name sortKey="Pouton, Colin W" sort="Pouton, Colin W" uniqKey="Pouton C" first="Colin W" last="Pouton">Colin W. Pouton</name><affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Scammells, Peter J" sort="Scammells, Peter J" uniqKey="Scammells P" first="Peter J" last="Scammells">Peter J. Scammells</name><affiliation wicri:level="1"><nlm:affiliation>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Electronic address: peter.scammells@monash.edu.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Medicinal Chemistry, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author><author><name sortKey="Porter, Christopher J H" sort="Porter, Christopher J H" uniqKey="Porter C" first="Christopher J H" last="Porter">Christopher J H. Porter</name><affiliation wicri:level="1"><nlm:affiliation>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia. Electronic address: chris.porter@monash.edu.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Drug Delivery, Disposition and Dynamics, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052, Australia; ARC Centre of Excellence in Convergent Bio-Nano Science and Technology, Monash Institute of Pharmaceutical Sciences, Monash University, 381 Royal Parade, Parkville, VIC 3052</wicri:regionArea><wicri:noRegion>VIC 3052</wicri:noRegion></affiliation></author></analytic><series><title level="j">Journal of pharmaceutical sciences</title><idno type="eISSN">1520-6017</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Higher lipid solubility of lipophilic salt forms creates new product development opportunities for high-dose liquid-filled capsules. The purpose of this study is to determine if lipophilic salts of Biopharmaceutical Classification System (BCS) Class I amlodipine and BCS Class III fexofenadine, ranitidine, and metformin were better lipid formulation candidates than existing commercial salts. Lipophilic salts were prepared from lipophilic anions and commercial HCl or besylate salt forms, as verified by (1)H-NMR. Thermal properties were assessed by differential scanning calorimetry and hot-stage microscopy. X-ray diffraction and polarized light microscopy were used to confirm the salt's physical form. All lipophilic salt forms were substantially more lipid-soluble (typically >10-fold) when compared to commercial salts. For example, amlodipine concentrations in lipidic excipients were limited to <5-10 mg/g when using the besylate salt but could be increased to >100 mg/g when using the docusate salt. Higher lipid solubility of the lipophilic salts of each drug translated to higher drug loadings in lipid formulations. In vitro tests showed that lipophilic salts solubilized in a lipid formulation resulted in dispersion behavior that was at least as rapid as the dissolution rates of conventional salts. This study confirmed the applicability of forming lipophilic salts of BCS I and III drugs to promote the utility of lipid-based delivery systems.</div></front></TEI><affiliations><list><country><li>Australie</li><li>France</li><li>États-Unis</li></country><region><li>Alsace (région administrative)</li><li>Grand Est</li><li>Oregon</li></region><settlement><li>Strasbourg</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Williams, Hywel D" sort="Williams, Hywel D" uniqKey="Williams H" first="Hywel D" last="Williams">Hywel D. Williams</name></noRegion><name sortKey="Ford, Leigh" sort="Ford, Leigh" uniqKey="Ford L" first="Leigh" last="Ford">Leigh Ford</name><name sortKey="Han, Sifei" sort="Han, Sifei" uniqKey="Han S" first="Sifei" last="Han">Sifei Han</name><name sortKey="Lim, Shea" sort="Lim, Shea" uniqKey="Lim S" first="Shea" last="Lim">Shea Lim</name><name sortKey="Porter, Christopher J H" sort="Porter, Christopher J H" uniqKey="Porter C" first="Christopher J H" last="Porter">Christopher J H. Porter</name><name sortKey="Pouton, Colin W" sort="Pouton, Colin W" uniqKey="Pouton C" first="Colin W" last="Pouton">Colin W. Pouton</name><name sortKey="Scammells, Peter J" sort="Scammells, Peter J" uniqKey="Scammells P" first="Peter J" last="Scammells">Peter J. Scammells</name></country><country name="États-Unis"><region name="Oregon"><name sortKey="Baumann, John" sort="Baumann, John" uniqKey="Baumann J" first="John" last="Baumann">John Baumann</name></region><name sortKey="Sullivan, Hannah" sort="Sullivan, Hannah" uniqKey="Sullivan H" first="Hannah" last="Sullivan">Hannah Sullivan</name><name sortKey="Vodak, David" sort="Vodak, David" uniqKey="Vodak D" first="David" last="Vodak">David Vodak</name></country><country name="France"><region name="Grand Est"><name sortKey="Igonin, Annabel" sort="Igonin, Annabel" uniqKey="Igonin A" first="Annabel" last="Igonin">Annabel Igonin</name></region><name sortKey="Benameur, Hassan" sort="Benameur, Hassan" uniqKey="Benameur H" first="Hassan" last="Benameur">Hassan Benameur</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000139 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000139 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:28549907
|texte= Transformation of Biopharmaceutical Classification System Class I and III Drugs Into Ionic Liquids and Lipophilic Salts for Enhanced Developability Using Lipid Formulations.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:28549907" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |